Clinical Trial Detail

NCT ID NCT01951690
Title Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Verastem, Inc.
Indications

lung non-small cell carcinoma

Therapies

Defactinib

Age Groups: adult

No variant requirements are available.